Nitric oxide for the evaluation and treatment of pulmonary hypertension in congenital heart disease.
The use of inhaled nitric oxide as a selective pulmonary vasodilator has expanded to include patients with congenital heart disease and pulmonary hypertension. The therapeutic and diagnostic roles of inhaled nitric oxide offer additional alternatives and benefits to these patients with pulmonary hypertension, particularly in the postoperative setting. This article reviews the background, mechanism of action, toxicities, and current clinical applications of inhaled nitric oxide in the child with congenital heart disease and pulmonary hypertension.
Kovalchin
J P
JP
Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Mott
A R
AR
Rosen
K L
KL
Feltes
T F
TF
D000280:Administration, Inhalation; D002648:Child; D006330:Heart Defects, Congenital / Q000150:complications* / Q000601:surgery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D007231:Infant, Newborn; D009569:Nitric Oxide / Q000008:administration & dosage / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014665:Vasodilator Agents; D009569:Nitric Oxide